VistaGen Therapeutics Inc Stock News

If you're searching for stocks under $15, look no further. These seven offerings, all priced below $15, present a unique opportunity for individual investors to profit from future development.

Finding possibilities in investing frequently depends on finding companies attached to rapid expansion and value generation. Examine these three prospects, each selling at less than $10 per share and

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapi

Finding undiscovered opportunities can result in significant profits in an investment landscape frequently controlled by well-known giants. These three obscure stocks have the potential to provide imp

Vistagen Therapeutics has proprietary platform technologies for developing innovative drugs for mental health disorders. The company's pipeline includes candidates for social anxiety disorder, major d

VistaGen Therapeutics is developing CNS drugs for anxiety, depression, and other disorders, with Fasedienol in phase 3 clinical trials. Fasedienol has advantages as a non-systemic, low-abuse anxiolyti

Menopause is among the female health conditions with the highest unmet need and has 'enormous potential for innovative treatments,' according to McKinsey.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals a

The mean of analysts' price targets for VistaGen Therapeutics, Inc. (VTGN) points to a 160% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agree

Investing in high-potential biotech stocks should catapult your portfolio to new heights. Picture this: a global biotech market valued at a whopping $1.55 trillion in 2023 is set to catapult to $3.08

Entering 2024, a shift toward optimism emerges in the market, with eased monetary policies potentially opening doors for penny stocks to rebound. Savvy investors, drawn to overlooked opportunities, ma

Despite the recent economic deceleration, positive factors like a tight labor market and strong consumer spending support a resilient U.S. economy. Goldman Sachs predicts increased state and local gov

Vistagen (VTGN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Positive results achieved in phase 3 PALISADE-2 study for Fasedienol, a potential new treatment for social anxiety disorder. It is estimated that there are roughly 25 million people in the United Stat

Vistagen Therapeutics, Inc. (NASDAQ:VTGN ) Q2 2024 Earnings Conference Call November 9, 2023 5:00 PM ET Company Participants Mark McPartland - Senior Vice President, Investor Relations Shawn Singh - C